Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo control / saline vehicle Clear all
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

NCT00571324
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
7 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 27, 2026, 6:01 PM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 27, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953
View directory record Official record
Conditions
Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
Interventions
Erythropoietin, Saline placebo
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
Up to 24 Hours
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 27, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

NCT01683747
View directory record Official record
Conditions
Shock, Sepsis, Hypotension, Critical Illness
Interventions
Tranexamic Acid, Control Intervention (Carrier fluid only)
Drug
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 27, 2026, 6:01 PM EDT
Terminated Phase 4 Interventional Results available

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

NCT01459666
View directory record Official record
Conditions
Scar
Interventions
Dysport (abobotulinumtoxinA), Bacteriostatic 0.9% Sodium Chloride (vehicle)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

NCT02493257
View directory record Official record
Conditions
Nonallergic Irritant Rhinitis
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Not applicable Interventional Results available

Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function

NCT02469077
View directory record Official record
Conditions
Chronic Pain
Interventions
6 week aerobic exercise intervention, Placebo, Morphine, naloxone
Behavioral · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

NCT03347708
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT, Saline Solution, Sodium Hyaluronate
Biological · Drug
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 27, 2026, 6:01 PM EDT
Recruiting Phase 1 Interventional

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

NCT06504160
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 27, 2026, 6:01 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

NCT07219771
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PTP-01, Placebo control / saline vehicle
Biological · Other
Lead sponsor
Doron Therapeutics Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • La Mesa, California • West Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 27, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

NCT00348439
View directory record Official record
Conditions
Vitreoretinal Traction Syndrome
Interventions
Plasmin, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Not applicable Interventional

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

NCT01095276
View directory record Official record
Conditions
Atelectasis, Ventilation, Mechanical
Interventions
Pulmozyme (nebulized dornase alpha), Saline
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

NCT03229759
View directory record Official record
Conditions
Preoperative Skin Preparation
Interventions
Octenidine Dihydrocloride in aqueous solution, Vehicle Control, Saline Control
Drug · Other
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 27, 2026, 6:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

NCT00835328
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 27, 2026, 6:01 PM EDT
Not yet recruiting Phase 2 Interventional

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

NCT07756346
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
13 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

NCT00770146
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Mipomersen sodium, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
62
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 27, 2026, 6:01 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

NCT03608033
View directory record Official record
Conditions
IgA Nephropathy
Interventions
OMS721, Vehicle (D5W or saline)
Biological · Other
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

NCT00949663
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

NCT00289341
View directory record Official record
Conditions
Prostate Cancer
Interventions
vaccine vehicle only, DC/LNCaP
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 27, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

NCT03763929
View directory record Official record
Conditions
Stroke, Acute
Interventions
Trans-Sodium Crocetinate, Placebo
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 2 Interventional

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

NCT04154072
View directory record Official record
Conditions
Parkinson Disease
Interventions
NLY01, Vehicle
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus

NCT00798915
View directory record Official record
Conditions
Diabetes
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

NCT00179998
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Recombinant Human DNase (Pulmozyme), Placebos
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 30 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 27, 2026, 6:01 PM EDT
Completed Phase 1 Interventional

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

NCT02723539
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
MBN-101, Placebo
Drug
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Fresno, California • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 27, 2026, 6:01 PM EDT